Vakcine protiv covid-19 kod pacijenata sa hipertenzijom

IV Međunarodni kongres UZPS Empatija zdravstvenih profesionalaca – put do razumevanja drugih, (str. 199-210)

AUTOR(I) / AUTHOR(S):Samela ZELIĆ

Download Full Pdf   

DOI: https://doi.org/10.46793/IVUZPS.199Z

SAŽETAK / ABSTRACT:

Rad istražuje patofiziološke interakcije između SARS-CoV-2 virusa i hipertenzije, te njihove potencijalne implikacije na antihipertenzivnu terapiju. SARS-CoV-2 koristi ACE2 receptore za ulazak u stanice, a istovremeno smanjuje ekspresiju ACE2, što može dovesti do povećanja angiotenzina II i pogoršanja simptoma bolesti. Hipertenzija, kao i upotreba lijekova poput ACE inhibitora (ACEi), angiotenzinskih receptora blokatora (ARB) i beta-blokatora, može utjecati na ovu dinamiku, s mogućim posljedicama za infektivni odgovor i liječenje.

Povezanost između vakcinacije protiv COVID-19 i hipertenzije također je istražena, pri čemu je pokazano da hipertenzija može smanjiti odgovor na vakcine. Također, upotreba antihipertenzivnih lijekova u kontekstu COVID-19 pandemije i njihove potencijalne interakcije sa SARS-CoV-2 bila je predmet brojnih istraživanja, a rezultati su bili različiti, ali sugeriraju da bi neki lijekovi mogli smanjiti rizik od težih oblika bolesti.

KLJUČNE REČI / KEYWORDS:

SARS-CoV-2, hipertenzija, ACE2, antihipertenzivna terapija, COVID-19, vakcinacija, ACE inhibitori, ARB, beta-blokatori, kalcijum, upalni odgovor, citokinska oluja.

LITERATURA / REFERENCES:

  1. Bojanić J. Nova dostignuća u razvoju vakcina. Scripta medica. 2015; 46: p. 137-142.
  2. Angeli F, Reboldi G, Trapasso M, Verdecchia P. Hypertension after COVID-19 vaccination. Giornale Italiano di Cardiologia (2006). 2006; 23(1): p. 10-14.
  3. Li W, Moore M, Vasilieva N. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 246(6965): p. 450-454.
  4. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2004; 203(2): p. 631-637.
  5. Sanchis-Gomar F, Lavie C, Mehra M, Henry B, Lippi G. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. In Mayo Clinic Proceedings; 2020: Elsevier. p. 1445-1453.
  6. Wilczynski S, Wenceslau C, McCarthy C, Webb R. A cytokine/bradykinin storm comparison: what is the relationship between hypertension and COVID-19? American Journal of Hypertension. 2021; 34(4): p. 304.
  7. De Oliveira A, Priviero F, Lima V, Webb R, Nunes K. COVID-19 and ROS Storm: What is the Forecast for Hypertension. American Journal of Hypertension. 2021; 34(8): p. 779.
  8. Swamy S, Koch C, Hannah-Shmouni F, Schiffrin E, Klubo-Gwiezdzinska J, Gubbi S. Hypertension and COVID-19: Updates from the era of vaccines and variants. Journal of clinical & translational endocrinology. 2022; 27.
  9. Vasanthakumar N. Can beta-adrenergic blockers be used in the treatment of COVID-19? Medical hypotheses. 2020; 142.
  10. Tan K, Harazim M, Tang B, Mclean A, Nalos M. The association between premorbid beta blocker exposure and mortality in sepsis—a systematic review. Critical Care. 2019; 23: p. 1-12.
  11. Casciano J, Duchemin N, Lamontagne R, Steel L, Bouchard M. Hepatitis B virus modulates store-operated calcium entry to enhance viral replication in primary hepatocytes. PloS one. 2017; 12(2).
  12. Sagara I, Ellis R, Dicko A, Niambele M. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+ CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine. 2009; 27(52).
  13. Caldeira D, Alves M, e Melo R, António P, Cunha N, Nunes-Ferreira A, et al. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis. IJC Heart & Vasculature. 2020; 31.
  14. Flacco M, Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020; 106(19).
  15. Hakeam H. Association of angiotensin-converting enzyme inhibitors and angiotensin II blockers with severity of COVID-19: a multicenter, prospective study. Journal of cardiovascular pharmacology and therapeutics. 2021; 26(3).
  16. Wang Y, Chen B, Li Y. The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID‐19 patients: a systematic review and meta‐analysis. Journal of medical virology. 2021; 93(3).
  17. Hippisley-Cox J, Young D, Coupland C, Channon K, San Tan P, Harrison D, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020; 109(19).
  18. Solaimanzadeh I. Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19. Cureus. 2020; 12(5).
  19. Alsagaff M. Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021; 15(5).
  20. Ren L, Yu S, Xu W, Overton J, Chiamvimonvat N, Thai P. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis. Journal of cardiology. 2021; 77(5).
  21. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. European heart journal. 2020; 41(22).
  22. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020; 63(8).
  23. Baden L. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine. 2021; 384(5).
  24. Polack F. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine. 2020; 38(27).
  25. Agrawal B. Heterologous immunity: role in natural and vaccine-induced resistance to infections. Frontiers in immunology. 2019; 10.
  26. Mysore V. Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens. Med. 2021; 2(9).
  27. Bouhanick B, Montastruc F, Tessier S, Brusq C, Bongard V, Senard J, et al. Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal. European Journal of Clinical Pharmacology. 2021; 77(12).